I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follow
SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ --I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follows: 11th Credit Suisse China Investment Conference (Virtual) One-on-one and small group meetings: November 2 & 5, 2020 For more information, please contact your Credit Suisse representative. 15th Citi China Investor Conference 2020 (Virtual) One-on-one and small group meetings: November 3-5, 2020 For more information, please contact your Citi representative. CICC Investment Forum (Beijing) 2020 Location: Kerry Hotel, Beijing, China One-on-one and small group meetings: November 11-12, 2020 For more information, please contact your CICC representative. Nomura Investment Forum 2020 (Virtual) Large group meetings: November 13, 2020 For more information, please contact your Nomura representative. Goldman Sachs Asia Pacific Healthcare Forum 2020 (Virtual) One-on-one and small group meetings: November 16-18, 2020 For more information, please contact your Goldman Sachs representative. Jefferies London Healthcare Conference (Virtual) Webcast link: https://wsw.com/webcast/jeff141/imab/1814025 The webcast will also be available under “Event Calendar” on IMAB’s IR website at http://ir.i-mabbiopharma.com/ . One-on-one meetings: November 17-19, 2020 For more information, please contact your Jefferies representative. About I-Mab I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn and WeChat. For more information, please contact: I-Mab Jielun Zhu, Chief Financial Officer Gigi Feng, Chief Communications Officer Investor Inquiries: Burns McClellan, Inc. (Americas and Europe) The Piacente Group, Inc. (Asia) View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-november-conferences-301161665.html SOURCE I-Mab | ||
Company Codes: NASDAQ-NMS:IMAB |